Elicio Therapeutics, Inc. 8-K

What Happened

• On June 15, 2026, Elicio Therapeutics, Inc. (ELTX) announced top-line results from its randomized Phase 2 AMPLIFY‑7P study in adjuvant mutant KRAS‑driven pancreatic ductal adenocarcinoma and outlined a refined Phase 3 development strategy for its investigational candidate ELI‑002 7P. The company issued a press release and held a conference call; those materials are attached to the 8‑K as Exhibit 99.1 (press release) and Exhibit 99.2 (presentation). The report was signed by Robert Connelly, President and CEO.

Key Details

• Date filed: June 15, 2026 (Current Report on Form 8‑K, Item 8.01 Other Events).
• Study: randomized Phase 2 AMPLIFY‑7P in adjuvant mutant KRAS‑driven pancreatic ductal adenocarcinoma.
• Program: ELI‑002 7P — company announced a refined Phase 3 development strategy following the Phase 2 results.
• Attachments: press release (Exhibit 99.1) and conference call presentation (Exhibit 99.2) included with the filing.

Why It Matters

• Clinical results and the planned Phase 3 strategy are key development milestones for Elicio and are material information investors monitor because they affect the program’s path toward potential regulatory and commercial value. Investors should review the attached press release and presentation for trial details, endpoints, and next steps, and watch for subsequent updates on Phase 3 timing and execution.